Navigation Links
Second-line CML drugs evoke faster response than front-line therapy
Date:12/7/2009

NEW ORLEANS ― Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.

Initial therapy for CML remains imatinib, a Novartis drug known as Gleevec, which has increased the five-year survival rate for the disease from 50 percent to 90 percent of patients. In separate clinical trials, M. D. Anderson researchers are comparing nilotinib, a Novartis drug known as Tasigna, and dasatinib, a Bristol-Myers Squibb drug known as Sprycel, to historical results from earlier trials of imatinib.

"More patients taking nilotinib or dasatinib are achieving complete responses more quickly than they do on either of two daily doses of imatinib," said Jorge Cortes, M.D., professor in M. D. Anderson's Leukemia Department and leader of both studies.

For example, 96 percent of those taking nilotinib and 94 percent of those on dasatinib reached a complete cytogenetic response at six months, compared with 54 percent of those taking 400 mg a day of imatinib and 85 percent of those taking 800 mg. Over the longer term up to 30 months, complete cytogenetic response induced by the two drugs is comparable to that of the higher-dose imatinib.

Complete cytogenetic response is the absence of the defective chromosome that causes the disease.

CML is caused by an abnormality known as the Philadelphia chromosome that produces an aberrant protein, Bcr-Abl, which causes the overproduction of one type of white blood cell that drives the disease. All three drugs are tyrosine kinase inhibitors, which block the action of Bcr-Abl. Nilotinib and dasatinib target more variations of the protein and often work after imatinib has failed. Both are approved by the U.S. Food and Drug Administration for patients who can't tolerate imatinib or whose CML resists the drug.

The dasatinib trial has enrolled 62 patients with previously untreated early stage CML taking either 50 mg twice daily or 100 mg once a day. Among 50 patients followed for at least three months, 49 (98 percent) achieved complete cytogenetic response. Major molecular response, a more stringent measure of remission, was reached in 35 patients (70 percent) with five (10 percent) achieving complete molecular response.

The researchers have dropped the twice daily arm of the trial, keeping the 100 mg once a day arm open because it has produced higher rates of major molecular response with fewer side effects.

The nilotinib trial has enrolled 65 patients with the 400mg twice daily dose producing complete cytogenetic responses in 50 of 51 patients (98 percent) followed for at least three months. Major molecular response has been achieved in 32 patients (63 percent) with 12 (24 percent) achieving complete molecular response.

All patients in both trials are alive, and enrollment continues. Side effects are being closely monitored and some patients in each trial had their treatment reduced or temporarily interrupted because of toxicities. Side effects are manageable and similar to those seen for imatinib, Cortes said.

Early results for both comparisons

Months on therapy Percent of patients with Complete Cytogenetic Response
Dasatinib Imatinib 400mg Imatinib 800mg
3 82 37 63
6 94 54 85
12 98 65 89
18 89 67 89
24 84 67 88
30 83 67 89

Months on therapy Percent of patients with Complete Cytogenetic Response (Number of valuable patients)
Nilotinib Imatinib 400mg Imatinib 800mg
3 90 37 63
6 96 54 85
12 97 65 89
18 93 67 89
24 93 67 88
30 92 67 89


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. AHF/India Cares Provides Second-line AIDS Drugs to Activists in India
2. Activist Groups Plea to Indian Prime Minister: Rollout Second-Line AIDS Treatment!
3. Simvastatin Leads Pfizers Lipitor in Second-Line Patient Share for the Treatment of Dyslipidemia
4. More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro
5. Seroquels First- and Second-Line Patient Share Has Grown Since Last Years Analysis of Prescribing Trends in Bipolar Disorder
6. AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
7. New review suggests caution on drugs to raise good cholesterol
8. Can cancer drugs combine forces?
9. Study provides hope that some transplant patients could live free of antirejection drugs
10. Study provides hope that some transplant patients could live free of anti-rejection drugs
11. RA Drugs Linked to Slight Skin Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – is set to return to the esteemed Quaker Ridge Golf ...
(Date:5/4/2016)... ... May 04, 2016 , ... The ... research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against ... on May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, ...
(Date:5/4/2016)... ... May 04, 2016 , ... IsoComforter, ... the introduction of the innovative newly improved Iso-Hip Wrap. The newly designed ... plush design enhances comfort and enables the patient to enjoy the benefits of ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... The ... Day to recognize chaplains for their valuable support to patients and their families, and ... May 10. , To mark Spiritual Care Day, SCA has sent “Thank You Chaplain” ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... New Jersey , May 4, 2016 ... its successful completion of an alternative public offering (APO). ... wholly owned operating company, Valeritas, Inc. and a private ... common stock at $5.00 per share. Under ... on May 3, 2016, Valeritas Holdings, Inc. will trade ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology: